The conventional treatment for high-risk pre-threshold retinopathy of prematurity (ROP) involves traditional laser therapy targeting the non-vascularized retina, eliminating cells producing Vascular Endothelial Growth Factor (VEGF) [6]. Here, VEGFA is linked to retinopathy of prematurity.